WuXi PharmaTech (NYSE:
WX) reported 3Q10 EPS of $0.27 after adjusting for intangible amortization and transaction-related items, Jefferies & Company reports.
“Revenue was $83.8M,” Jefferies & Company writes. “Our estimate was $0.19 on $80.2M. The company issued 2010 revenue guidance of $330M - $333M versus current consensus of $329M.”
WuXi PharmaTech currently trades at $16.25.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
